Adverum Biotechnologies, Inc.

Adverum Biotechnologies, Inc.

ADVMยทNASDAQ

$4.36

+0.0000%
HealthcareBiotechnology

Adverum Biotechnologies, Inc., a clinical-stage gene therapy company, develops gene therapy product candidates to treat ocular and rare diseases. Its lead product candidate is ADVM-022, a single intravitreal injection gene therapy candidate used for the treatment of patients with chronic retinal, including wet age-related macular degeneration and diabetic macular edema. Adverum Biotechnologies, Inc. has license and collaboration agreements with University of California; Cornell University; GenSight; Lexeo; and Virovek. The company was formerly known as Avalanche Biotechnologies, Inc. and changed its name to Adverum Biotechnologies, Inc. in May 2016. Adverum Biotechnologies, Inc. was incorporated in 2006 and is headquartered in Redwood City, California.

At a Glance

Live Snapshot
Market Cap$96.26M
EPS-6.6200
P/E Ratio-0.71
Earnings Date04/21/2026

No Dividend Yield Data

ADVM has not reported any dividend yield values in the available annual periods.

No Dividend Payout Ratio Data

ADVM has not reported any dividend payout ratio values in the available annual periods.

No Net Dividends Paid Data

ADVM has not reported any net dividends paid values in the available annual periods.

Adverum Biotechnologies, Inc.

Adverum Biotechnologies, Inc. Dividend History

ADVM ยท NASDAQ
10Y CAGR +0%
Latest $0
Annual $0
Stable dividend payments
Last Period: +0%

ADVM Dividend Payment History

ADVM ยท NASDAQ
DeclarationEx-DatePayment DateDividendAdjustedFrequencyGrowth
No dividend payment history available
advm

Adverum Biotechnologies, Inc. Payout Ratio Analysis

ADVM ยท NASDAQ
Dividends Paid
0.00
2024
Net Income
-130.93M
2024
Payout Ratio
0.00%
2024

Dividend Sustainability Analysis

Payout Ratio
0.00%

Conservative payout with excellent safety margin. Company retains significant earnings for growth, acquisitions, or building cash reserves. Dividend is highly sustainable.

FCF Payout Ratio
0.0%

Negative free cash flow while paying dividends is a major red flag. Company burning cash and cannot sustain dividend without external financing.

Sustainability
At Risk

Dividend appears unsustainable based on current metrics. High probability of reduction or elimination. Proceed with caution.